Alirocumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Oct 3, 2017 → Feb 13, 2020
NCT ID
NCT03156621About Alirocumab + Placebo
Alirocumab + Placebo is a phase 3 stage product being developed by Sanofi for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03156621. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03156621 | Phase 3 | Completed |
| NCT02938949 | Approved | Completed |
| NCT01959971 | Phase 1 | Completed |
| NCT01604824 | Phase 2 | Completed |
| NCT01266876 | Phase 2 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia